Expert Overviews

Efficacy of Current Anti-Obesity Drugs

SURMOUNT-1—Results of The First Phase 3 Obesity Trial with The Novel GIP/GLP-1 Receptor Agonist Tirzepatide

Bariatric and Metabolic Surgery

Potential Treatment Prioritization Strategies

Stage of T1D

Effect of QW Semaglutide on Weight Change and Metabolic Control in People with T1D: 6-Month Results from the Real-World STEMT Trial

4T Study: Tighter Glucose Target Setting With Early CGM Initiation Further Improves A1c in Youth With T1D

Stem Cell-Derived Fully Differentiated Islet Cells for T1D

Effect of Low-Dose Empagliflozin on Glucose Control in Suboptimally Controlled Adults with T1D on a Closed-Loop Delivery System

HHF among African American Compared With White Individuals With T2D on Empagliflozin—RWD

Risk Factor Control and Risk of HHF in Diabetic Patients

Effect of Hyperketonemia on Cardiac Efficiency in Patients with HF and T2D 640

Prescribing Patterns of SGLT2i in Patients With HF With or Without T2D

Rationale for using diabetes technology

T1D Exchange: Automated Insulin Delivery Use among T1D Exchange Registry participants

Disparities in Treatment Options for Hypoglycemia: the Role of Diabetes-Related Technologies

4T Study: Tighter Glucose Target Settings with Early CMG Initiation Further Improves A1c in Youth with T1D

Glycemic Outcomes over 12 Months in Very Young Children with the Omnipod® 5 Automated Insulin Delivery System

The Insulin-Only Bionic Pancreas Pivotal Trial: a Comparison of the Bionic Pancreas Using Rapid-Acting Insulin Aspart Versus Standard Care and Versus the Bionic Pancreas Using Insulin Aspart or Insulin Lispro

Differences in Closed Loop Algorithms: Benefits and Limitations. First Look at the New Data from >20K People and 6,701 Patient-Years of a Closed-Loop System Use (Control-IQ)

Eliminating Manual Meal Bolusing: a Feasibility Trial Using MiniMedTM 780G and Hand Gesture Algorithms